Consumer Empowerment as a Solution to Health System Financing.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 77, doi. 10.2165/00019053-200018001-00010
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2000 AND VI 18 AND IP 3
Results: 21
1
2
Healthcare Systems: A New European Model?
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 85
- By:
- Publication type:
- Article
3
Payment Systems and Considerations of Case Mix - Are Diagnosis-Related Groups Applicable in Japan?
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 95, doi. 10.2165/00019053-200018001-00012
- By:
- Publication type:
- Article
4
Concluding Remarks.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 111, doi. 10.2165/00019053-200018001-00013
- By:
- Publication type:
- Article
5
Introduction.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 1, doi. 10.2165/00019053-200018001-00001
- By:
- Publication type:
- Article
6
US Economic Revolution: Mapping the Future of Healthcare.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 3, doi. 10.2165/00019053-200018001-00002
- By:
- Publication type:
- Article
7
The Patient Rights Movement in Europe.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 7, doi. 10.2165/00019053-200018001-00003
- By:
- Publication type:
- Article
8
Post-Modern Drug Evaluation: The Deconstruction of Evidence-Based Regulation.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 15, doi. 10.2165/00019053-200018001-00004
- By:
- Publication type:
- Article
9
The Distribution of Sales Revenues from Pharmaceutical Innovation.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 21, doi. 10.2165/00019053-200018001-00005
- By:
- Publication type:
- Article
10
Is There a Link Between Pharmaceutical Consumption and Improved Health in OECD Countries?
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 33, doi. 10.2165/00019053-200018001-00006
- By:
- Publication type:
- Article
11
The Increasing Necessity for Market-Based Pharmaceutical Prices.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 47, doi. 10.2165/00019053-200018001-00007
- By:
- Publication type:
- Article
12
Reimbursement for New Health Technologies: Breakthrough Pharmaceuticals as a 20th Century Challenge.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 59, doi. 10.2165/00019053-200018001-00008
- By:
- Publication type:
- Article
13
Restructuring French Hospitals: Some Problems and Some Solutions.
- Published in:
- PharmacoEconomics, 2000, v. 18, n. 3, p. 69, doi. 10.2165/00019053-200018001-00009
- By:
- Publication type:
- Article
14
The need for an iterative process for assessing economic outcomes associated with SSRIs.
- Published in:
- 2000
- By:
- Publication type:
- journal article
15
The epidemic of Alzheimer's disease. How can we manage the costs?
- Published in:
- 2000
- By:
- Publication type:
- journal article
16
Costs of deep foot infections in patients with diabetes mellitus.
- Published in:
- 2000
- By:
- Publication type:
- journal article
17
Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
- Published in:
- 2000
- By:
- Publication type:
- journal article
18
Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma.
- Published in:
- 2000
- By:
- Publication type:
- journal article
19
Cost effectiveness of abciximab during routine medical practice.
- Published in:
- 2000
- By:
- Publication type:
- journal article
20
The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach.
- Published in:
- 2000
- By:
- Publication type:
- journal article
21
Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.
- Published in:
- 2000
- By:
- Publication type:
- journal article